J&J raises prices as Dems introduce bills aimed at lowering drug costs

Drug pricing reform has bipartisan support, but that hasn't stopped pharma from enacting hikes — in part because such moves have been vital to growth.

By Jacob Bell • Jan. 11, 2019

Grassley to zoom in on drug pricing, insurance mergers as Senate panel chair

The new Republican chairman of the Senate Finance Committee laid out his agenda, including allowing cheaper drug imports from Canada.

By David Lim • Jan. 10, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

As pharmas revert to regular price hikes, Azar threatens action with 'fighting words'

The Health and Human Services Secretary praised Merck & Co., Gilead Sciences and Amgen by name Wednesday on Twitter before declaring the industry "must stop" raising list prices.

By Andrew Dunn • Jan. 9, 2019

Bluebird proposes installment plan for LentiGlobin gene therapy

The biotech company would receive further payments only if LentiGlobin keeps working, according to a payment idea the company rolled out Tuesday.

By Kristin Jensen • Jan. 9, 2019

Blockbuster … or lackluster? Four steps to a winning label

Do you have enough data to back-up how your product is better than others? Following these four steps can help you prepare for competition in the marketplace.

Jan. 8, 2019

Pharma DTC spending outpaces rest of medical marketing, JAMA study finds

Companies spent $30 billion on medical marketing in 2016, up 60% from two decades ago. Direct-to-consumer spending more than tripled over that time.

By Andrew Dunn • Jan. 7, 2019

Esperion licenses European rights on cholesterol drug for $300M

While Esperion plans to file for approval in the first half of 2019, a long-term CV outcomes study lingers with an expected readout in 2022. 

By Andrew Dunn • Jan. 4, 2019

Drugmakers open new year with price increases on dozens of medicines

Allergan, Biogen and Bristol-Myers were among the companies that raised list prices, suggesting criticism hasn't halted a return to "business as normal" for the industry.

By Ned Pagliarulo • Jan. 2, 2019

Acorda wins FDA nod for Parkinson's drug

An OK for Inbrija may help Acorda rebound from a damaging court ruling that opened the door for generic competition to the biotech's only marketed drug.

By Ned Pagliarulo • Dec. 24, 2018

Our 10 best stories of 2018

Pharma boards, cell therapy, AI and cancer drug ads feature in BioPharma Dive's top articles of the past 12 months.

By Ned Pagliarulo • Dec. 21, 2018

Gene therapy could be cost effective in SMA, but not at $4M

A report from ICER found Novartis' experimental Zolgensma could be more cost-effective than Biogen's Spinraza in treating spinal muscular atrophy.

By Ned Pagliarulo • Dec. 21, 2018

Trump drug ad proposal earns support from insurers, medical groups

Pharma strongly opposes the idea, however, arguing it would spark confusion and paint a misleading picture of what drugs end up costing consumers.

By Ned Pagliarulo • Dec. 19, 2018

Novartis, Pfizer withdraw drug applications in Europe

Novartis pulled canakinumab, with regulators leaning against approval, and Pfizer withdrew its Humira biosimilar.

By Andrew Dunn • Dec. 17, 2018

American leaders' distrust in science a 'dangerous situation,' BIO chair says

John Maraganore, the chair of biotech's largest trade group, said he's concerned the recent controversy over gene-edited babies could trigger knee-jerk reactions.

By Andrew Dunn • Dec. 14, 2018

BIO chair: More drugmakers should pledge to not hike prices

"The industry can do better," Alnylam CEO John Maraganore told BioPharma Dive, arguing that scrutiny of rising drug prices isn't going away. 

By Andrew Dunn • Dec. 13, 2018

Kalé​o, facing criticism, launches generic overdose treatment at cut price

At $178 for a pack of two, Kalé​o's authorized copy of its own Evzio will cost far less than the $4,100 list price it set for the branded version.

By Ned Pagliarulo • Dec. 12, 2018

WPP plots return to growth through 'simpler offer,' refreshes brand identity

The holding group plans to focus squarely on four business areas going forward, but more agency mergers don't appear to be in the cards for now.

By Peter Adams • Dec. 11, 2018

Roche wins key cancer drug approval, but taking on Merck remains a challenge

Despite Tecentriq's OK in frontline metastatic lung cancer, one Wall Street analyst cut sales forecasts for the drug by billions over the next five years.

By Ned Pagliarulo • Dec. 11, 2018

Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

ViiV and majority owner GSK are focused on two-drug regimens, while rival Gilead is betting big on its recently approved triplet Biktarvy. 

By Jacob Bell • Dec. 11, 2018

J&J's Actelion pays out $360M to resolve kickback claims

The Justice Department claimed the pharma donated to a charity to help pay Medicare patients' copays for its drugs.

By Suzanne Elvidge • Dec. 10, 2018

FedEx, Walgreens partner for next-day delivery of prescription drugs

The company's move is designed to head off Amazon's entry into home delivery as well as compete with CVS' similar service.

By Andy Burt • Dec. 7, 2018

Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'

Looming over clinical victories seen at ASH was a problematic question: How exactly will health systems pay for these powerful yet pricey therapies?

By Jacob Bell • Dec. 5, 2018

AbbVie nets 7th Humira biosimilar deal, pushing Pfizer entry to 2023

The settlement allows Pfizer to launch its copy in the U.S. at the end of 2023; a European launch can go ahead as soon as approval comes through.

By Suzanne Elvidge • Dec. 5, 2018

Biotech of the Year: Spark Therapeutics

The biotech's gene therapy Luxturna, priced at $850,000 per patient, is testing a healthcare system not designed for transformative, one-time treatments.

By Jacob Bell • Dec. 3, 2018

Drug Launch of the Year: Amgen and Novartis' Aimovig

Choosing a lower-than-expected price was an unusual, disruptive move, but one that could pay off as Amgen and Novartis fend off rivals.

By Andrew Dunn • Dec. 3, 2018